» Articles » PMID: 36358814

Epigenetic Reprogramming of Kaposi's Sarcoma-Associated Herpesvirus During Hypoxic Reactivation

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2022 Nov 11
PMID 36358814
Authors
Affiliations
Soon will be listed here.
Abstract

The biphasic life cycle (latent and lytic) of Kaposi's sarcoma-associated Herpesvirus (KSHV) is regulated by epigenetic modification of its genome and its associated histone proteins. The temporal events driving epigenetic reprogramming of the KSHV genome on initial infection to establish latency has been well studied, but the reversal of these epigenetic changes during lytic replication, especially under physiological conditions such as hypoxia, has not been explored. In this study, we investigated epigenetic reprogramming of the KSHV genome during hypoxic reactivation. Hypoxia induced extensive enrichment of both transcriptional activators and repressors on the KSHV genome through H3K4Me3, H3K9Me3, and H3K27Me3, as well as histone acetylation (H3Ac) modifications. In contrast to uniform quantitative enrichment with modified histones, a distinct pattern of RTA and LANA enrichment was observed on the KSHV genome. The enrichment of modified histone proteins was due to their overall higher expression levels, which was exclusively seen in KSHV-positive cells. Multiple KSHV-encoded factors such as LANA, RTA, and vGPCR are involved in the upregulation of these modified histones. Analysis of ChIP-sequencing for the initiator DNA polymerase (DNAPol1α) combined with single molecule analysis of replicated DNA (SMARD) demonstrated the involvement of specific KSHV genomic regions that initiate replication in hypoxia.

Citing Articles

Hypoxic reactivation of Kaposi's sarcoma associated herpesvirus.

Singh R, Torne A, Robertson E Cell Insight. 2024; 3(6):100200.

PMID: 39391006 PMC: 11466537. DOI: 10.1016/j.cellin.2024.100200.


HIV-associated cancers and lymphoproliferative disorders caused by Kaposi sarcoma herpesvirus and Epstein-Barr virus.

Lurain K, Ramaswami R, Krug L, Whitby D, Ziegelbauer J, Wang H Clin Microbiol Rev. 2024; 37(3):e0002223.

PMID: 38899877 PMC: 11391709. DOI: 10.1128/cmr.00022-23.


Investigation of key miRNAs and Target-mRNA in Kaposi's sarcoma using bioinformatic methods.

Wang T, Zheng J, Pan Y, Zhuang Z, Zeng Y Heliyon. 2024; 10(8):e29502.

PMID: 38660282 PMC: 11041027. DOI: 10.1016/j.heliyon.2024.e29502.


Insight into the Epigenetics of Kaposi's Sarcoma-Associated Herpesvirus.

Srivastava A, Srivastava A, Singh R Int J Mol Sci. 2023; 24(19).

PMID: 37834404 PMC: 10573522. DOI: 10.3390/ijms241914955.


Hypoxia and hypoxia-inducible factors in Kaposi sarcoma-associated herpesvirus infection and disease pathogenesis.

Davis D, Shrestha P, Yarchoan R J Med Virol. 2023; 95(9):e29071.

PMID: 37665216 PMC: 10502919. DOI: 10.1002/jmv.29071.

References
1.
Chen L, Lagunoff M . Establishment and maintenance of Kaposi's sarcoma-associated herpesvirus latency in B cells. J Virol. 2005; 79(22):14383-91. PMC: 1280215. DOI: 10.1128/JVI.79.22.14383-14391.2005. View

2.
Cohen J . Herpesvirus latency. J Clin Invest. 2020; 130(7):3361-3369. PMC: 7324166. DOI: 10.1172/JCI136225. View

3.
Bechtel J, Liang Y, Hvidding J, Ganem D . Host range of Kaposi's sarcoma-associated herpesvirus in cultured cells. J Virol. 2003; 77(11):6474-81. PMC: 155009. DOI: 10.1128/jvi.77.11.6474-6481.2003. View

4.
Barrett L, Dai L, Wang S, Qin Z . Kaposi's sarcoma-associated herpesvirus and extracellular vesicles. J Med Virol. 2021; 93(6):3294-3299. DOI: 10.1002/jmv.26780. View

5.
Arvanitakis L, Mesri E, Nador R, Said J, Asch A, Knowles D . Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 1996; 88(7):2648-54. View